<DOC>
	<DOC>NCT00567203</DOC>
	<brief_summary>The objective of this study is to evaluate the safety, tolerability, and efficacy of two dose regimens of PF-3463275 compared with placebo added to ongoing atypical antipsychotic therapy for cognitive deficits in subjects with chronic symptoms of schizophrenia.</brief_summary>
	<brief_title>A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Diagnosis of schizophrenia In stable treatment with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone for at least 2 months Stable symptoms of schizophrenia for at least 3 months. Subjects with a psychiatric disorder other than schizophrenia Substance dependence or abuse Women who have child bearing potential.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>